Gotham Asset Management LLC purchased a new stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the third quarter, Holdings Channel reports. The institutional investor purchased 39,478 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,763,000. Gotham Asset Management LLC owned about 0.26% of Eagle Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of EGRX. BlackRock Fund Advisors increased its position in shares of Eagle Pharmaceuticals by 87.0% in the third quarter. BlackRock Fund Advisors now owns 769,869 shares of the specialty pharmaceutical company’s stock valued at $53,891,000 after buying an additional 358,134 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $48,318,000. Essex Investment Management Co. LLC purchased a new position in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $1,016,000. Bank of New York Mellon Corp increased its position in shares of Eagle Pharmaceuticals by 124.5% in the third quarter. Bank of New York Mellon Corp now owns 93,265 shares of the specialty pharmaceutical company’s stock valued at $6,529,000 after buying an additional 51,725 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Eagle Pharmaceuticals by 226.0% in the third quarter. PNC Financial Services Group Inc. now owns 41,002 shares of the specialty pharmaceutical company’s stock valued at $2,871,000 after buying an additional 28,424 shares during the last quarter.
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) traded up 0.03% during trading on Friday, hitting $71.99. 123,806 shares of the stock were exchanged. The stock has a market cap of $1.11 billion, a P/E ratio of 46.87 and a beta of 1.54. Eagle Pharmaceuticals, Inc. has a 12 month low of $33.02 and a 12 month high of $87.78. The stock’s 50 day moving average price is $71.33 and its 200 day moving average price is $67.38.
TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark laws. The correct version of this piece of content can be viewed at http://sleekmoney.com/39478-shares-in-eagle-pharmaceuticals-inc-egrx-acquired-by-gotham-asset-management-llc/1655315.html.
Several equities analysts recently commented on EGRX shares. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $84.00 price target on the stock in a report on Friday, November 4th. Mizuho downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $78.00 price target on the stock. in a report on Wednesday, November 16th. RBC Capital Markets reiterated an “outperform” rating and set a $86.00 price target (down from $93.00) on shares of Eagle Pharmaceuticals in a report on Monday, January 9th. Finally, Royal Bank Of Canada upped their price target on shares of Eagle Pharmaceuticals from $80.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, November 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $85.83.
In other Eagle Pharmaceuticals news, major shareholder Proquest Investments Iv, L.P. sold 65,114 shares of Eagle Pharmaceuticals stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $85.16, for a total transaction of $5,545,108.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sander A. Flaum sold 5,000 shares of Eagle Pharmaceuticals stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $78.66, for a total transaction of $393,300.00. Following the transaction, the director now directly owns 11,374 shares in the company, valued at $894,678.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 80,114 shares of company stock worth $6,688,508. Insiders own 18.80% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/39478-shares-in-eagle-pharmaceuticals-inc-egrx-acquired-by-gotham-asset-management-llc/1655315.html
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.